ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Nilotinib, a second-generation BCR-ABL tyrosine kinase inhibitor (TKI) is approved for the treatment of adult patients with newly diagnosed Ph+ CML in chronic phase (CP) (Tasigna 2015).